Filing Details
- Accession Number:
- 0001209191-22-043100
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-07-25 16:12:26
- Reporting Period:
- 2022-07-22
- Accepted Time:
- 2022-07-25 16:12:26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1322505 | Albireo Pharma Inc. | ALBO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1741553 | Jason Duncan | C/O Albireo Pharma, Inc. 53 State Street, 19Th Floor Boston MA 02109 | Chief Legal Officer And Gc | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-07-22 | 106 | $24.68 | 16,138 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-22 | 238 | $24.45 | 15,900 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-25 | 93 | $24.40 | 15,807 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-25 | 220 | $23.66 | 15,587 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $25.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- Represents 962 shares of common stock and 15,176 restricted stock units. Includes 236 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2022.
- Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021.
- Represents 724 shares of common stock and 15,176 restricted stock units.
- Represents 944 shares of common stock and 14,863 restricted stock units.
- Represents 724 shares of common stock and 14,863 restricted stock units.
Billionaire Hedge Funds
